DMAAR
Drugs Made In America Acquisition Corp. RightsKey Statistics
About Drugs Made In America Acquisition Corp. Rights
Drugs Made In America Acquisition Corp. (DMAAR) is a special purpose acquisition company targeting the revitalization of domestic pharmaceutical manufacturing to address pressing healthcare needs and supply chain vulnerabilities. Harnessing the expertise of a seasoned management team, DMAAR aims to identify and merge with established pharmaceutical players, positioning itself to leverage growth opportunities in an evolving market. By prioritizing resilience and self-sufficiency in American healthcare, DMAAR offers institutional investors a compelling opportunity for both substantial returns and a positive societal impact within the pharmaceutical sector.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -1.46% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.22 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 18.80% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $20.40M |
| Float | $27.90M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Volatility is currently expanding
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on DMAAR and any ticker you trade — then tracks every position and per-strategy win rate.